Upcoming Events

BDD is on the road. Here is a list of upcoming events and conferences we will be attending. If you would like to talk to us or meet with us at any of these events please use any of the links below to reach out to our team.


Our Events Team

Dr Carol Thomson

Dr Carol Thomson

Chief Executive Officer

Carol was co-founder and COO of Drug Delivery International Ltd for three years prior to becoming CEO of BDD Pharma. With more than 20 years’ experience of management in the sciences sector, Carol has developed strong operational management and leadership skills and has led the growth of BDD as an integrated development and clinical trials company, including two successful funding rounds. Carol has a degree in Genetics from the University of Glasgow and a PhD from the University of Sheffield.

Calum Stevens

Calum Stevens

Commercial Director

Calum Stevens is Commercial Director and has been with BDD Pharma for more than 12 years. Responsibilities include strategizing and implementing sales and marketing campaigns, managing the company branding and facilitating client acquisition. Calum has previous experience with successfully running & founding his own company, Lomond Marine. Externally Calum sits on the board at Carers Link as a Non-Executive Director and as Chairman of Communications Subgroup. He is also a member of the Management Committee of the Loch Lomond Rescue Boat. Calum studied Marine Biology at the University of Aberdeen.

Darren Quinn

Darren Quinn

Senior Business Development Executive

Laura has been with BDD for over 12 years and has more than 15 years experience in the pharmaceutical sector. She has extensive expertise in GMP manufacturing and clinical trial management. Laura is responsible for business operations across the clinical and development divisions of BDD, leading our expert teams to deliver on BDD’s vision and strategy. Laura has an MChem from Heriot Watt University.


“With industry leading scientific expertise in clinical imaging and drug product design, BDD was an ideal partner for early stage clinical evaluation of complex drug products and implementation of new imaging approaches.” – Matt Burke – Vice President, Technical Operations & Product Development.
Formerly Senior Director, Head of Drug Delivery and CMC Leader at GSK

“We are happy to collaborate with BDD Pharma – their technology as well as integrated setup for early exploratory clinical testing is a great match for us and allow us to advance our Parkinson´s disease program towards patients.” – Anders Brandt Elvang – Chief Business Officer

“BDD was able to think out of the box in approaching some unusual formulation challenges in our development program. We were able to work interactively with BDD to get our new drug formulation program off the ground.” – Thomas Jozefiak – Chief Scientific Officer

“Cingulate appreciates BDD’s collaborative approach which consistently takes into consideration our priorities. This has allowed us to progress our clinical program for our ADHD clinical candidate. We certainly can recommend BDD for anyone seeking a reliable partner.” – Laurie Myers – Chief Operating Officer

For more than 20 years, BDD has provided expertise in early phase clinical research for the pharmaceutical industry using gamma scintigraphic imaging techniques. Gamma scintigraphic studies enable the visualisation of formulation behaviour in man and are a powerful tool in product development. Through conducting these evaluative clinical studies, BDD Scientists have gained a unique understanding of how pharmaceutical products work in vivo.

In 2010, we founded sister company Drug Delivery International (DDI) Ltd, to develop our patented controlled release technology OralogiK™ and offer formulation development services to our clients. In 2017, DDi and Bio-images Research came together as BDD Pharma Ltd to offer our clients combined formulation development and clinical services.

Our experience of biopharmaceutics is what drives our science and sets us apart from our competitors. We understand the complexities of drug development and have created an integrated clinical and manufacturing service enabling rapid in vivo evaluation of novel products saving our clients considerable time and expense during product development.

BDD continue to invest in future technologies and research (particularly in the modified release field) to ensure we offer our clients solutions to their challenges as well as providing the patients of tomorrow with enhanced treatments to improve quality of life.

Our success is built upon solid scientific ability, strengthened by shared values across the company. Our commitment to our clients is at the forefront of everything we do.